Skip to content

Effects of OCFA-rich DHA algal oil on metabolism of obese/overweight children

Effects of OCFA-rich DHA algal oil on metabolism of obese/overweight children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116327
Enrollment
Unknown
Registered
2026-01-08
Start date
2026-01-10
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity/overweight

Interventions

DHA algal oil group:DHA algae oil, take once daily with meals
C15:0 DHA algal oil group:C15:0 DHA algal oil, take once daily with meals
Placebo group:Placebo, once daily, taken with food

Sponsors

Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age: Children aged 12-15 years, any gender; 2. According to the World Health Organization's child growth standards, children are considered obese if their body mass index (BMI) exceeds 2 standard deviations above the mean BMI for children of the same age and sex, i.e., a BMI equal to or greater than the obesity threshold for the corresponding age and sex group; 3. Parents (or legal guardians) are willing to provide basic demographic information and complete the required surveys; 4. If the child has previously used related algal oil or fish oil products, they must have discontinued use for at least 4 weeks; 5. The child and their guardian understand the experimental procedures and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals with severe liver and kidney dysfunction, cardiovascular diseases, endocrine disorders (such as thyroid dysfunction), or other diseases affecting lipid metabolism or intestinal function; 2. Individuals who have used antibiotics, probiotics, or other drugs that may affect gut microbiota within the past 3 months; 3. Individuals allergic to algae; 4. Individuals who have recently had significant changes in diet or are participating in other weight loss programs; 5. Any other conditions that the researcher believes may hinder compliance or interfere with the completion of the study; 6. Subjects whom the researcher believes cannot or is unwilling to follow the protocol or have any other condition that may hinder compliance or interfere with the completion of the study; 7. Subjects currently participating in clinical trials or who have received study drugs within 180 days after screening; 8. Subjects currently using other algal oil or fish oil products; 9. Subjects who have not given informed consent.

Design outcomes

Primary

MeasureTime frame
Body composition ;Blood lipidomics;BMI-z;lipid profiles;blood glucose;

Secondary

MeasureTime frame
Basic information on demography;Mental Health Questionnaire;Questionnaires on exercise, satiety, gastrointestinal symptoms, faecal pattern and frequency of bowel movements.;Blood biochemistry and immune markers;Gut Microbiota;conitive function;SCFAs;

Countries

China

Contacts

Public ContactChenxi Cai

School of Public Health, Xiamen University

chenxicai@xmu.edu.cn+86 592 218 6358

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026